Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
December 01, 2021 16:05 ET | Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
August 24, 2021 10:44 ET | Sorrento Therapeutics, Inc.
MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
CellepathicRX logo
CellepathicRx Selected to Speak During Innovation Showcase at International CTIA Wireless(r) 2012 in New Orleans
May 09, 2012 09:30 ET | CellepathicRX
CLEVELAND, May 9, 2012 (GLOBE NEWSWIRE) -- CellepathicRx will speak at the CTIA Executive Forum during International CTIA WIRELESS® 2012, taking place May 8-10 at the Ernest N. Morial Convention...